Key facts
- A South Korean biotech company is developing a new treatment for 'Ozempic face'.
- The treatment utilizes donated human fat to restore lost facial volume.
- This approach is intended as a more natural and sustainable alternative to existing cosmetic fillers.
A South Korean biotech firm is pioneering a novel approach to combat 'Ozempic face,' a common side effect of popular weight-loss drugs like Ozempic and Wegovy that leads to a gaunt appearance due to rapid fat loss. The company's innovative treatment involves using donated human fat to restore lost facial volume, offering a potentially more natural and sustainable alternative to traditional cosmetic fillers such as hyaluronic acid or silicone.
The development comes as the popularity of GLP-1 agonist drugs continues to surge, creating a growing demand for solutions to mitigate their aesthetic side effects. The biotech firm's strategy focuses on leveraging biological materials for regenerative purposes, aiming to provide a solution that integrates seamlessly with the body's natural tissues.